Tenaya Therapeutics, Inc.
TNYA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.23 | 0.03 | 0.04 | 0.19 |
| FCF Yield | -5.90% | -15.83% | -37.51% | -15.05% |
| EV / EBITDA | -10.50 | -2.31 | -0.88 | -5.89 |
| Quality | ||||
| ROIC | -22.11% | -20.91% | -20.77% | -23.09% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 0.67 | 0.86 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.83% | 32.94% | -26.37% | 7.13% |
| Safety | ||||
| Net Debt / EBITDA | 2.14 | 2.38 | 1.64 | -0.41 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -142.38 | 0.00 | 0.00 |